Particulars (Rs. in cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 741.00 | 505.00 | 47.00% | 720.00 | 3.00% |
EBITDA | 265.00 | 181.00 | 46.00% | 249.00 | 6.00% |
EBITDA Margin (%) | 35.76% | 35.84% | (8 bps) | 34.58% | 118 bps |
PAT | 96.00 | 122.00 | -21.00% | 89.00 | 8.00% |
EPS (Rs.) | 6.73 | 9.08 | -26.00% | 6.11 | 10.00% |
Source: Company Filings; stockaxis Research
Q2FY25 Result Highlights
Eris Lifesciences reported mixed set of earnings for the quarter ended Q2FY25. The
company registered robust revenue growth of 47% YoY aided by integration of Swiss
Parenterals and synergies from Biocon’s portfolio. The management cited base
organic business growth at 7% for H1Y25. Chronic and sub-chronic segment together
accounts for 85% of the revenue. Among the businesses acquired in FY24, Biocon acquisition
reported healthy run-rate of Rs.1.34bn in Q2 (flat QoQ), while Swiss Parenterals
reported Rs.820mn revenue vs Rs.730mn in Q1. However, Gross Margin saw a sharp contraction
by 641 bps to 74.9% due to significant changes in product/ business mix. Consolidated
EBITDA witnessed a solid growth of 46% YoY to Rs.265 cr while margins stood flat
at 35.7%. Base business OPM was up by 374bps YoY. PAT declined 21% YoY to Rs.96
cr. The PAT figures came in below estimates.
FY25 Business Guidance
Other Key Highlights
Eris Lifesciences Ltd. delivered mixed set of numbers in Q2FY25. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to sustain at +35% as revenue scales up from recent acquisitions which is currently operating at sub optimal profitability. Acquisitions, including Swiss Parenterals and Biocon's injectable business, are expected to contribute to ERIS growth trajectory in the medium term. ERIS is also working on launching over 20 'first-to-market' products, showcasing a strong focus on innovation. The company's robust product pipeline and expected patent expirations in key therapeutic areas contribute to a positive outlook. ERIS Lifesciences Ltd exhibits strong growth potential, driven by its innovative product pipeline, strategic acquisitions, and anticipated performance in key therapeutic segments.
The company has multiple growth levers such as broad-based offerings in the derma segment, opportunities in cardio metabolic market with patent expirations, and benefits of operating leverage, as revenue scales up from these acquisitions. We expect ERIS to outperform the industry over the near to medium term, as it has established its presence in the cardiac and diabetic segments. Additionally, the new product pipeline and patent expiries provide robust growth visibility in the future. Through the organic and inorganic routes, ERIS has enhanced its offerings in dermatology, nephrology, women’s healthcare, injectables, and intensified its diabetology/cardio-vascular portfolio. At a CMP of Rs.1305, the stock is trading at 33x FY26E. We maintain HOLD rating on the stock.
Particulars (Rs. in cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 741.00 | 505.00 | 47.00% | 720.00 | 3.00% |
COGS | 186.00 | 95.00 | 96.00% | 181.00 | 3.00% |
Gross Profit | 555.00 | 410.00 | 35.00% | 539.00 | 3.00% |
Gross Margin (%) | 74.90% | 81.19% | (641 bps) | 74.86% | 4 bps |
Employee Benefit expenses | 126.00 | 99.00 | 27.00% | 133.00 | -5.00% |
Other expenses | 165.00 | 131.00 | 26.00% | 157.00 | 5.00% |
EBITDA | 265.00 | 181.00 | 46.00% | 249.00 | 6.00% |
EBITDA Margin (%) | 35.76% | 35.84% | (8 bps) | 34.58% | 118 bps |
Depreciation expenses | 80.00 | 42.00 | 90.00% | 76.00 | 5.00% |
EBIT | 185.00 | 139.00 | 33.00% | 173.00 | 7.00% |
Finance cost | 59.00 | 16.00 | 269.00% | 60.00 | -2.00% |
Other Income | 5.00 | 3.00 | 67.00% | 2.00 | 150.00% |
PBT | 129.00 | 126.00 | 2.00% | 115.00 | 12.00% |
Tax expenses | 33.00 | 4.00 | 725.00% | 26.00 | 27.00% |
PAT | 96.00 | 122.00 | -21.00% | 89.00 | 8.00% |
EPS (Rs.) | 6.73 | 9.08 | -26.00% | 6.11 | 10.00% |